PLAT and intracerebral hemorrhage: It is estimated that between 1–16% of SM patients receive thrombolysis with tissue plasminogen activator (tPA), with 0.5% of these patients developing a symptomatic intracerebral hemorrhage.15 Such unnecessary interventions can add up, with an estimated cost of treatment of $5,400 per admission.16 These factors necessitate the early identification of an SM patient to spare the unwarranted tests and interventions.